Does Semaglutide Affect the Heart? What the Evidence Shows

Step 1: What the SELECT trial established about heart risk

The clearest cardiac evidence for semaglutide 2.4mg (Wegovy) comes from the SELECT trial, a large cardiovascular outcomes study in adults with obesity and pre-existing heart disease but without type 2 diabetes. Over roughly five years, participants on semaglutide had a 20% lower rate of major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) compared with those on placebo. That result was significant enough for the MHRA to add a cardiovascular-risk-reduction indication to Wegovy's UK licence, separate from its weight-management use.

This matters because it moves the conversation beyond weight alone. Semaglutide's GLP-1 receptor activity appears to have direct effects on blood vessels and inflammation, not just indirect benefits from losing weight. Researchers are still unpicking exactly which mechanisms drive the cardiac protection, reduced body weight, lower blood pressure, improved lipid profiles, and direct vessel effects all seem to contribute.

For a grounding on what Wegovy is licensed to do in the UK and how it works as a treatment, our Wegovy overview page covers the full picture. If you want to go deeper on the cardiac side specifically, our page on whether semaglutide affects your heart covers the mechanisms and evidence in more detail.

Step 2: The heart-rate question, what a small rise actually means

Semaglutide typically raises resting heart rate by around one to four beats per minute. That figure appears consistently across trials, including STEP 1, published in the New England Journal of Medicine, and has been observed with other GLP-1 medicines too. For most people the increase is clinically small and does not produce symptoms.

For people with certain pre-existing arrhythmias or those already on rate-controlling medicines, even a modest rise is worth discussing beforehand. Prescribers look at the full cardiac history at consultation, not just the average trial result. One practical point our prescribers hear regularly: people sometimes delay starting treatment until after a holiday or a busy patch, that hesitation is understandable, but for anyone with a cardiac history it is also a reason to get the clinical conversation done sooner rather than later, so the decision is made carefully and not under time pressure.

The broader question of Wegovy and heart health covers how prescribers balance these competing signals in practice.

Step 3: Heart-related side effects to recognise during treatment

The most commonly reported side effects on semaglutide are gastrointestinal (nausea, diarrhoea, constipation, and reflux) rather than cardiac. These tend to be most noticeable at the start of treatment or after a dose increase, and they usually ease as the body adjusts.

The side effects that warrant prompt medical attention are different. Severe, persistent abdominal pain that radiates towards the back could indicate pancreatitis, which the MHRA's 2026 Drug Safety Update identifies as an infrequent but serious risk across GLP-1 medicines. Signs of dehydration (particularly if prolonged vomiting or diarrhoea prevents adequate fluid intake) can put extra strain on the kidneys and, indirectly, on cardiac function. Any chest pain, shortness of breath, or palpitations that feel unusual should be assessed by a clinician promptly, even if they seem unrelated to the medicine.

Side effects can be reported directly to the MHRA using the Yellow Card scheme, which helps regulators monitor real-world safety data. The NHS medicines page for semaglutide also lists what to watch for, written specifically for patients: NHS guidance on semaglutide.

Step 4: When a cardiac history changes the clinical conversation

Having heart disease does not automatically rule out semaglutide. The SELECT trial enrolled people with established cardiovascular disease, and the results were favourable for that group. What changes is the depth of assessment. A prescriber needs to know about any recent cardiac events, current medications (particularly those affecting heart rate or rhythm), and whether blood pressure is stable.

Certain conditions do affect suitability. People with a history of heart failure have not been as extensively studied in semaglutide's weight-management trials, so prescribers approach this more cautiously. Drug interactions also matter: semaglutide slows gastric emptying, which can affect how other medicines are absorbed, including some cardiac drugs. If you take antidepressants alongside cardiac medicines, the question of how Wegovy interacts with antidepressants is one example of the kind of interaction check a prescriber carries out.

Semaglutide also has effects beyond the heart. Its influence on liver health is an active area of research, with a conditional UK approval for a specific liver condition granted in July 2026. For anyone who is pregnant or planning a pregnancy, our page on how semaglutide affects pregnancy is an important read, as this is another factor prescribers consider when someone has multiple health considerations.

If you would like to explore whether treatment is appropriate for your situation, you are welcome to speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered clinician who can weigh up your individual history properly.